Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Attention Deficit Hyperactivity Disorder (ADHD)
Clinical Trial
NCT02618434Last updated: 12/4/2025
SUPN
SUPERNUS PHARMACEUTICALS, INC.